Stock Financial Ratios, Dividends, Split History
NWBO / Northwest Biotherapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||96.48|
|Enterprise Value ($M)||128.01|
|Book Value ($M)||-80.82|
|Book Value / Share||-0.19|
|Price / Book||-1.19|
|NCAV / Share||-0.27|
|Price / NCAV||-0.86|
|Income Statement (mra) ($M)|
|Sales Revenue Net||336,000.00|
|Revenue From Grants||336,000.00|
|Sales Revenue Goods Net||0.00|
|Earnings Per Share Diluted||-0.31|
|Earnings Per Share Basic||-0.31|
|Earnings Per Share Basic And Diluted||-0.31|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||-36.49|
|Cash from Investing||0.21|
|Cash from Financing||0.21|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1072379|
|SIC 2834 - Pharmaceutical Preparations|
Stock splits are used by Northwest Biotherapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2017-11-11 - Asif
The Company is focused on developing personalized immune therapies for cancer. Northwest Biotherapeutics has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company’s lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. The Company is continuing to collect data “events” in the Phase III trial, and the data set is gradually maturing. The Company is also working on preparations for Phase II trials of DCVax-L for other indications. The Company’s second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of cancers. The Company is working on preparations for P...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors. (299-5)
Note: This article was written several days ago and published on Avisol Capital Partners's Total Pharma Tracker, a marketplace service dedicated to helping investors sift through the noise and find biotech gems. Become a trial subscriber for free today! (25-1)
as of ET